Type 1 Diabetes Trial, Recruiting NCT06670625 Sponsor: Lund University Condition: Type 1 Diabetes
Back to Type 1 Diabetes

Type 1 Diabetes Trial, Recruiting

NCT06670625
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The baby must be between 13 and 17 weeks old at the time of joining the trial.
  • The baby must have a higher-than-average genetic chance (7–10%) of developing signs of type 1 diabetes by age 6, based on specific gene patterns identified through genetic testing.
  • Babies without a close family member with type 1 diabetes may be eligible if they carry certain specific gene combinations and have a genetic risk score above a set level (the exact score depends on whether the baby is male or female — confirm with trial site).
  • Babies who have a close family member (such as a parent or sibling) with type 1 diabetes may be eligible based on their gene type, regardless of their genetic risk score (confirm with trial site for specific gene combinations).
  • The baby's parent(s) or legal guardian(s) must sign a written consent form agreeing to take part.

Who may not be able to join:

  • Babies who have any health condition, illness, or are receiving a treatment that could interfere with the study or put them at risk, as decided by the research doctors.
  • Babies who were born prematurely (before 36 weeks of pregnancy).
  • Babies who have any condition that might make it difficult to follow the study's requirements consistently.
  • Babies who have already been diagnosed with diabetes before joining the trial.
  • Babies who are currently taking part in another medical study or using an experimental drug.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Helena Elding Larsson, PhD, Lund University

Phone: +464039113

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Lund University
Registry
ClinicalTrials.gov
Start date
15 March 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Beta-cell health; Beta-cell health

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov